drugset
drugset / Trial / NCT05574374

Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects

NCT05574374 ↗

Phase 1 Completed 36 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects

Timeline

Start
2022-09-21
Primary completion
2023-03-06
Completion
2023-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ABEPRAZAN Small molecule — —
Subject Clopidogrel Small molecule — —
Subject DWC202203 Unknown — —

Indications

No indication recorded.